The exploding head syndrome.

M W Green

doi:10.1007/s11916-001-0043-9

Home/Archive/PubMed

PubMed · 11309216

The exploding head syndrome.

M W Green

View original source ↗Export metadata ↓

Abstract

This article reviews the features of an uncommon malady termed "the exploding head syndrome." Sufferers describe terrorizing attacks of a painless explosion within their head. Attacks tend to occur at the onset of sleep. The etiology of attacks is unknown, although they are considered to be benign. Treatment with clomipramine has been suggested, although most sufferers require only reassurance that the spells are benign in nature.

Explore related subjects

Clomipramine Headache Humans Perception Selective Serotonin Reuptake Inhibitors Syndrome Journal Article Review

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

M W Green. 2001. The exploding head syndrome.. https://doi.org/10.1007/s11916-001-0043-9

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2000

On the pharmacotherapy of obsessive-compulsive disorder: is a consensus possible?

OBJECTIVE: To examine the efficacy and tolerability of clomipramine compared with the selective serotonin reuptake inhibitors (SSRIs) in the treatment of obsessive-compulsive disorder (OCD), bearing in mind the recent Expert Consensus Guidelines recommendation to use clomipramine after 2 to 3 failed SSRI trials. METHOD: The literature on the pharmacotherapy of OCD was critically examined. RESULTS: The available research evidence is not conclusive but suggests that clomipramine possesses greater anti-obsessional efficacy than do the SSRIs. In addition, when clomipramine is presented to patients in a positive way, and properly used in small initial doses with gradual increases, it seems to be tolerated as well as the SSRIs. CONCLUSION: Recently expressed opinions that clomipramine should be used to treat OCD after 2 to 3 failed SSRI trials are not supported by research evidence. Both clomipramine and the SSRIs may be used as first-line treatments for OCD.

Clomipramine↗

PubMed1999

Double-blindness procedure did not mask giving of medication in panic disorder.

BACKGROUND: The purpose of this study was to measure the degree to which patients and their treating physicians correctly guessed whether patients were on an active treatment (paroxetine or clomipramine) or pill-placebo, and whether correctness of these guesses was related to treatment outcome. METHODS: Ninety-five panic disorder patients, randomized to receive double-blind treatment with paroxetine, clomipramine or placebo for twelve weeks, were asked half-way through this period to classify treatment as active or placebo. Medical doctors were asked the same. RESULTS: Both patients and physicians guessed correctly to a degree much greater than would be expected by chance whether the patient was on an active treatment. Neither patients nor physicians were good at estimating correctly whether a patient was on a placebo. There was a trend approaching significance for patients on a placebo, whose physicians believed that they were on active treatment, to have a higher rating of symptom improvement than those patients who were correctly guessed to be on placebo. CONCLUSION: The 'double-blindness' procedure did not mask the giving of antidepressive medication in panic disorder. There is some evidence that physicians who incorrectly classify patients on a placebo as receiving active treatment relate this to better treatment outcome.

Clomipramine↗

PubMed1996

Does brief dynamic psychotherapy reduce the relapse rate of panic disorder?

BACKGROUND: Although panic disorder can be effectively alleviated by drug treatment, the relapse rate is high. By adding brief dynamic psychotherapy focused on the psychosocial vulnerability of patients with panic disorder to an established drug treatment regimen, we hypothesized that this would result in a lower relapse rate after pharmacotherapy. METHODS: Patients with panic disorder (defined by DSM-III-R) were randomized to treatment with either clomipramine for 9 months (n = 20), or clomipramine for 9 months combined with 15 weekly sessions of brief dynamic psychotherapy (n = 20). Measures of anxiety and depression were collected at intake and at regular intervals. The patients had blind follow-up interviews at 6, 12, and 18 months after beginning treatment. RESULTS: All patients in both groups became free of panic attacks within 26 weeks of the start of treatment. On termination of pharmacotherapy, the relapse rate was significantly higher in the clomipramine-only group during the follow-up period. There were significantly lower scores for most anxiety measures in the clomipramine plus psychotherapy group at the 9-month follow-up. CONCLUSION: The addition of brief dynamic psychotherapy to treatment with clomipramine significantly reduces the relapse rate of panic disorder compared with clomipramine treatment alone.

Clomipramine↗